| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 34,064 | 41,499 | 35,405 | 41,895 |
| Short-term investments | 63,673 | 77,083 | 93,849 | 95,528 |
| Prepaid expenses and other current assets | 1,483 | 1,863 | 1,107 | 989 |
| Total current assets | 99,220 | 120,445 | 130,361 | 138,412 |
| Total property and equipment | 8,354 | 8,207 | 8,146 | NaN |
| Less accumulated depreciation | 3,701 | 3,318 | 2,957 | NaN |
| Property and equipment, net | 4,653 | 4,889 | 5,189 | 5,072 |
| Operating lease right-of-use assets | 2,255 | 2,527 | 2,792 | 3,052 |
| Long-term investments | NaN | NaN | 5,108 | 10,199 |
| Restricted cash | 194 | 203 | 202 | 201 |
| Other assets | 1,510 | 1,653 | 1,647 | 1,647 |
| Total assets | 107,832 | 129,717 | 145,299 | 158,583 |
| Accounts payable | 1,162 | 2,277 | 996 | 1,163 |
| Accrued expenses and other current liabilities | 8,740 | 12,215 | 12,711 | 11,120 |
| Operating lease liabilities, current | 1,152 | 1,172 | 1,184 | 1,148 |
| Total current liabilities | 11,054 | 15,664 | 14,891 | 13,431 |
| Operating lease liabilities, non-current | 1,263 | 1,537 | 1,805 | 2,115 |
| Total liabilities | 12,317 | 17,201 | 16,696 | 15,546 |
| Common stock, 0.001 par value 500,000,000 shares authorized as of march 31, 2026 and december 31, 2025 38,745,032 and 31,648,856 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively | 38 | 31 | 31 | 31 |
| Additional paid-in capital | 389,396 | 387,255 | 384,356 | 380,562 |
| Accumulated other comprehensive income | 4 | 111 | 112 | 106 |
| Accumulated deficit | -293,923 | -274,881 | -255,896 | -237,662 |
| Total stockholders' equity | 95,515 | 112,516 | 128,603 | 143,037 |
| Total liabilities and stockholders' equity | 107,832 | 129,717 | 145,299 | 158,583 |
Acrivon Therapeutics, Inc. (ACRV)
Acrivon Therapeutics, Inc. (ACRV)